Summit Therapeutics (SMMT) Other Non-Current Assets (2021 - 2026)

Summit Therapeutics (SMMT) has reported Other Non-Current Assets for 6 consecutive years, with $8.4 million the latest figure, recorded in Q2 2026.

• Quarterly Other Non-Current Assets rose 29.65% year-over-year to $8.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.4 million (up 29.65% YoY) and the FY2025 annual result came in at $7.2 million, up 182.77% from the prior year.
• Other Non-Current Assets grew to $8.4 million in Q2 2026 per SMMT's latest filing, from $8.2 million in the prior quarter.
• Over the last five years, Other Non-Current Assets for SMMT reached as high as $8.4 million in Q2 2026 and fell as low as $140000.0 in Q3 2022.
• A 5-year average of $3.3 million and a median of $2.2 million in 2024 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 2994.29% — and 2024, when it sank 56.99%.
• Year by year, Other Non-Current Assets stood at $577000.0 in 2022, then jumped by 649.05% to $4.3 million in 2023, then plunged by 41.05% to $2.5 million in 2024, then jumped by 182.77% to $7.2 million in 2025, then advanced by 17.25% to $8.4 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $8.4 million, $8.2 million, and $7.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.